Perspective Therapeutics (CATX) Status Update summary

Platform and Pipeline Overview

• Proprietary radiopharmaceutical platform uses alpha-emitting 212Pb isotope for targeted tumor cell killing with minimized off-target effects, aiming to change oncology by internalizing radiation to treat cancer from within.

• Pipeline includes VMT01 for melanoma, VMT-α-NET for neuroendocrine tumors, and a FAP-targeted agent entering trials mid-year, with three clinical-stage programs and multiple preclinical assets.

• Robust manufacturing and supply chain enable ready-to-administer products and timely delivery of medicines.

• Theranostics approach de-risks development by imaging patients pre-treatment and enables personalized treatment.

• Perspective Therapeutics leverages a proprietary 212Pb generator for isotope supply.

Clinical Program: VMT-α-NET for Neuroendocrine Tumors

• VMT-α-NET targets SSTR2, highly expressed in neuroendocrine tumors and other cancers; Fast Track Designation granted.

• Ongoing multi-center, dose-escalation Phase 1/2a trial in PRRT-naive, SSTR2-positive patients, with expansion into other SSTR2+ tumor types planned.

• Patient population: median age 63, mostly white, with a median of one prior systemic therapy.

• [212Pb] VMT-α-NET uses proprietary chelator technology for both imaging and therapy.

Safety and Tolerability Findings

• No dose-limiting toxicities, grade 4/5, or serious adverse events observed; safety profile remains favorable with only mild hematologic adverse events and no treatment discontinuations.

• Renal function remained stable throughout the study.

• [212Pb] VMT-α-NET was well tolerated, supporting rationale for dose escalation.